Home | About the eMC | Help | Mobile
eMC - trusted, up to date and comprehensive information about medicines
Link to eMC medicine guides website
eMC homepage
Advanced search
Get Medicines Compendium UK app here

Novartis Pharmaceuticals UK Ltd
Frimley Business Park, Frimley, Camberley, Surrey, GU16 7SR
Telephone: +44 (0)1276 692 255
Fax: +44 (0)1276 698 449
Medical Information Direct Line: +44 (0)1276 698 370
Medical Information e-mail: medinfo.uk@novartis.com
Customer Care direct line: +44 (0)845 741 9442

Before you contact this company: often several companies will market medicines with the same active ingredient. Please check that this is the correct company before contacting them. Why?
Patient Information Leaflet last updated on the eMC: 09/08/2011
PIL EXJADE 125 mg, 250mg, 500mg dispersible tablets

When a pharmaceutical company changes an SPC or PIL, a new version is published on the eMC. For each version, we show the dates it was published on the eMC and the reasons for change.

Updated on 09/08/2011 and displayed until Current
Reasons for adding or updating:
  • Change due to harmonisation of PIL.
  • Change to MA holder contact details
Updated on 19/01/2011 and displayed until 09/08/2011
Reasons for adding or updating:
  • Change to date of revision
  • Change to drug interactions
Updated on 07/12/2009 and displayed until 19/01/2011
Reasons for adding or updating:
  • Change to date of revision
  • Change to warnings or special precautions for use
  • Change of contra-indications
  • Change to side-effects
  • Change to dosage and administration
  • Change to MA holder contact details
Updated on 09/04/2009 and displayed until 07/12/2009
Reasons for adding or updating:
  • Change to date of revision
  • Change to side-effects
Updated on 10/02/2009 and displayed until 09/04/2009
Reasons for adding or updating:
  • Change to drug interactions
Updated on 11/09/2008 and displayed until 10/02/2009
Reasons for adding or updating:
  • Change to date of revision
  • Change to warnings or special precautions for use
  • Change to side-effects
  • Change to drug interactions
Updated on 14/08/2007 and displayed until 11/09/2008
Reasons for adding or updating:
  • Change to warnings or special precautions for use
Updated on 27/12/2006 and displayed until 14/08/2007
Reasons for adding or updating:
  • New PIL for new product

Active Ingredients/Generics

 
  deferasirox